Volume 25, Number 8—August 2019
Intact Mycobacterium leprae Isolated from Placenta of a Pregnant Woman, China
Whether Mycobacterium leprae transmits from placenta to fetus remains unknown. We describe the case of a pregnant woman with untreated histoid leproma. Although her newborn was healthy, laboratory examination revealed intact M. leprae present in the placenta, suggesting that the placental barrier might prevent vertical dissemination of M. leprae.
Leprosy is an infectious disease caused by Mycobacterium leprae in susceptible persons. The disease affects the skin and peripheral nerves and, in later stages, can cause irreversible disability. Dissemination of M. leprae is thought to occur through nasal mucosa (1). However, in pregnant patients, whether M. leprae can transmit to the fetus remains unknown. We report the case of a pregnant woman who had histoid leproma and refused therapy until after birth. The Ethics Committee of the Chinese Academy of Medical Sciences’ Institute of Dermatology approved this study, and all persons provided informed consent before sample collection.
In December 2017, a pregnant woman sought care at the Chinese Academy of Medical Sciences’ Institute of Dermatology (Nanjing, China) with a 9-month history of asymptomatic multiple erythema and nodose lesions on her trunk. She had experienced dry skin and dysesthesia in both lower extremities for >10 years. In 2009, she had a sudden rash of erythema on her trunk and lower extremities, which was treated as eczema, without improvement. She began losing her eyebrows in 2015. Her pregnancy was discovered 3 months before admission. Since her illness onset, she had experienced no fevers or joint pain, and her family history was negative for leprosy.
Physical examination revealed multiple brown papules and firm nodules on her trunk and face (Figure, panels A, B). Superficial sensation was slightly impaired over the lower extremities. No peripheral nerve or superficial lymph node enlargement was observed. Her eyebrows were lost completely. A skin biopsy from her face revealed a subepidermal clear zone, numerous foamy histiocytes throughout the dermis, dense cellularity, and few perivascular lymphocytes. Prominent acid-fast bacilli were observed inside the dermis (Figure, panels C–E). PCR was performed to detect M. leprae DNA fragments of RLEP and FolP1. Samples from a facial lesion tested positive. Serologic examination of the patient’s peripheral blood using ELISA was positive for antibodies of NDO-BSA (IgM), MMP-II (IgG), and LID-1 (IgG) (Appendix Table 1).
The patient refused treatment, citing concern about adverse effects on the fetus. Her condition was monitored with ultrasounds at serial intervals. At 37 weeks’ gestation, her amniotic membranes ruptured. She was transferred to an isolated operating room and underwent a cesarean delivery. She delivered a healthy baby girl. At the patient’s request, she was housed separately from her infant, and she decided not to breast-feed. After delivery, the patient was treated with dapsone, rifampin, and clofazimine, in accordance with World Health Organization recommendations (2).
After delivery, we collected fresh samples from the patient, including breast milk, umbilical cord, umbilical cord blood, and placenta, as well as nasal mucosa swab and serum specimens from the patient, her newborn, and her elder daughter for bacterial and serologic analysis. Intact acid-fast bacilli were found in placenta homogenates from the patient (Figure, panel F; Appendix Figure). Serologic testing for NDO, MMP-II, and LID antibodies by ELISA were all positive in the patient, whereas only MMP-II and LID antibodies were found in the newborn (Appendix Table 1). We also conducted PCR testing of various samples; some results were positive for the mother and her elder daughter, but none were positive for the newborn (Appendix Table 2). One month later, serologic test results for the infant were almost negative for M. leprae antibodies (Appendix Table 3). The patient’s lesions resolved, and her family members were shown to be healthy during follow-ups.
Leprosy can be exacerbated during pregnancy and, without treatment, can cause permanent damage to the skin, nerves, and eyes because of suppression of cell-mediated immunity in pregnancy. Downgrading reactions can occur, especially in the third trimester (3). Therefore, treating leprosy during pregnancy is critical. For multibacillary leprosy patients, World Health Organization treatment guidelines recommend multidrug therapy using rifampin, dapsone, and clofazimine (2). These agents must never be used alone as monotherapy for leprosy nor be stopped during pregnancy (4).
Our patient refused treatment, citing concerns for adverse effects on the fetus; consequently, her condition dramatically worsened during the third trimester. Fortunately, no nerves or important organs were damaged. The patient’s breast milk was negative for DNA, RNA, and antibodies of M. leprae. Serum samples from umbilical cord blood were positive for DNA and IgG of M. leprae but negative for RNA and IgM. Notably, a substantial number of M. leprae organisms were detected in the placenta (Figure, panel F; Appendix Figure).
Our findings support the assumption that the placental barrier can effectively stop vertical transmission of leprosy as well as the consensus that breast-feeding by women receiving multidrug therapy is safe for infants, given that no DNA or RNA of M. leprae were detected in breast milk (5,6). Although antileprosy drugs can be excreted into breast milk, no adverse effects have been reported except skin discoloration in the infant because of clofazimine (7). The patient’s elder daughter’s serum sample and nasal mucosa swab specimen were positive for M. leprae DNA and RNA by PCR, confirming that she was an M. leprae carrier. Households experiencing such a situation need to be screened with regular follow-ups (8).
Dr. Zhiming Chen works at the Chinese Academy of Medical Sciences’ Institute of Dermatology and at Peking Union Medical College. His major research interests are cutaneous mycobacterial infection and genodermatosis.
We thank Lemuel Tsang for his invaluable suggestions during manuscript preparation.
This study was supported by the CAMS Innovation Fund for Medical Sciences (grant nos. 2016-I2M-1-005 and 2017-I2M-B&R-14) and Jiangsu Provincial Key Research and Development (grant no. BE2018619).
- Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg. 2008;78:518–21.
- World Health Organization. Chemotherapy of leprosy. World Health Organ Tech Rep Ser. 1994;847:1–24.
- Duncan ME, Pearson JM, Ridley DS, Melsom R, Bjune G. Pregnancy and leprosy: the consequences of alterations of cell-mediated and humoral immunity during pregnancy and lactation. Int J Lepr Other Mycobact Dis. 1982;50:425–35.
- World Health Organization. WHO model prescribing information: drugs used in leprosy [cited 2019 Jan 20]. https://apps.who.int/medicinedocs/en/d/Jh2988e
- Gimovsky AC, Macri CJ. Leprosy in pregnant woman, United States. Emerg Infect Dis. 2013;19:1693–4.
- Shale MJ. Women with leprosy. A woman with leprosy is in double jeopardy. Lepr Rev. 2000;71:5–17.
- Ozturk Z, Tatliparmak A. Leprosy treatment during pregnancy and breastfeeding: A case report and brief review of literature. Dermatol Ther (Heidelb). 2017;30:
- Listed N. The final push strategy to eliminate leprosy as a public health problem: questions and answers. Lepr Rev. 2002;73:279–81.
FigureCite This Article
Original Publication Date: July 06, 2019
1These authors contributed equally to and are co–first authors for this article.